NCT05200169View on ClinicalTrials.gov

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-AB1010 in Healthy Male Subjects

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

July 31, 2017

Primary Completion Date

September 1, 2017

Study Completion Date

September 1, 2017

Conditions
Healthy Volunteers
Interventions
DRUG

14C-AB1010

Oral solution of 14C radiolabelled AB1010 (200 mg per subject)

Trial Locations (1)

NG11 6JS

Quotient Sciences, Nottingham

Sponsors

Lead Sponsor

AB Science
All Listed Sponsors
lead

AB Science

INDUSTRY